Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.

Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaaw3163. doi: 10.1126/scitranslmed.aaw3163.

PMID:
31578242
2.

In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.

Racine T, Denizot M, Pannetier D, Nguyen L, Pasquier A, Raoul H, Saluzzo JF, Kobinger G, Veas F, Herbreteau CH.

J Infect Dis. 2019 Jun 5;220(1):41-45. doi: 10.1093/infdis/jiz068.

PMID:
30852585
3.

Immune parameters and outcomes during Ebola virus disease.

Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, Mateo M, Baillet N, Laouenan C, Raoul H, Mullaert J, Baize S.

JCI Insight. 2019 Jan 10;4(1). pii: 125106. doi: 10.1172/jci.insight.125106. [Epub ahead of print]

4.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.

5.

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

Ferraris O, Casalegno JS, Frobert E, Bouscambert Duchamp M, Valette M, Jacquot F, Raoul H, Lina B, Ottmann M.

Viruses. 2018 Sep 17;10(9). pii: E504. doi: 10.3390/v10090504.

6.

The European Virus Archive goes global: A growing resource for research.

Romette JL, Prat CM, Gould EA, de Lamballerie X, Charrel R, Coutard B, Fooks AR, Bardsley M, Carroll M, Drosten C, Drexler JF, Günther S, Klempa B, Pinschewer D, Klimkait T, Avsic-Zupanc T, Capobianchi MR, Dicaro A, Ippolito G, Nitsche A, Koopmans M, Reusken C, Gorbalenya A, Raoul H, Bourhy H, Mettenleiter T, Reiche S, Batten C, Sabeta C, Paweska JT, Eropkin M, Zverev V, Hu Z, Mac Cullough S, Mirazimi A, Pradel F, Lieutaud P.

Antiviral Res. 2018 Oct;158:127-134. doi: 10.1016/j.antiviral.2018.07.017. Epub 2018 Jul 29. Review.

7.

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S.

J Virol. 2018 May 29;92(12). pii: e02230-17. doi: 10.1128/JVI.02230-17. Print 2018 Jun 15.

8.

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X.

PLoS Med. 2018 Mar 27;15(3):e1002535. doi: 10.1371/journal.pmed.1002535. eCollection 2018 Mar.

9.

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02093-17. doi: 10.1128/AAC.02093-17. Print 2018 Jan. No abstract available.

10.

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW.

Sci Rep. 2017 Jun 22;7(1):4099. doi: 10.1038/s41598-017-03910-7.

11.

Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea.

Subtil F, Delaunay C, Keita AK, Sow MS, Touré A, Leroy S, Msellati P, Magassouba N, Baize S, Raoul H, Ecochard R, Barry M, Delaporte E, Etard JF; Postebogui Study Group.

Clin Infect Dis. 2017 Jun 15;64(12):1788-1790. doi: 10.1093/cid/cix210.

PMID:
28329169
12.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

13.

Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.

Piorkowski G, Jacquot F, Quérat G, Carbonnelle C, Pannetier D, Mentré F, Raoul H, de Lamballerie X.

Antiviral Res. 2017 Apr;140:95-105. doi: 10.1016/j.antiviral.2017.01.017. Epub 2017 Jan 26.

14.

Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.

Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E; Postebogui Study Group.

Lancet Infect Dis. 2017 May;17(5):545-552. doi: 10.1016/S1473-3099(16)30516-3. Epub 2017 Jan 14.

PMID:
28094208
15.

Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health.

Keita AK, Toure A, Sow MS, Raoul H, Magassouba N, Delaporte E, Etard JF; POSTEBOGUI Study Group.

Clin Microbiol Infect. 2017 Jun;23(6):412-413. doi: 10.1016/j.cmi.2016.11.005. Epub 2016 Nov 17. No abstract available.

16.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01305-16. doi: 10.1128/AAC.01305-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

17.

Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015.

Kerber R, Krumkamp R, Diallo B, Jaeger A, Rudolf M, Lanini S, Bore JA, Koundouno FR, Becker-Ziaja B, Fleischmann E, Stoecker K, Meschi S, Mély S, Newman EN, Carletti F, Portmann J, Korva M, Wolff S, Molkenthin P, Kis Z, Kelterbaum A, Bocquin A, Strecker T, Fizet A, Castilletti C, Schudt G, Ottowell L, Kurth A, Atkinson B, Badusche M, Cannas A, Pallasch E, Bosworth A, Yue C, Pályi B, Ellerbrok H, Kohl C, Oestereich L, Logue CH, Lüdtke A, Richter M, Ngabo D, Borremans B, Becker D, Gryseels S, Abdellati S, Vermoesen T, Kuisma E, Kraus A, Liedigk B, Maes P, Thom R, Duraffour S, Diederich S, Hinzmann J, Afrough B, Repits J, Mertens M, Vitoriano I, Bah A, Sachse A, Boettcher JP, Wurr S, Bockholt S, Nitsche A, Županc TA, Strasser M, Ippolito G, Becker S, Raoul H, Carroll MW, De Clerck H, Van Herp M, Sprecher A, Koivogui L, Magassouba N, Keïta S, Drury P, Gurry C, Formenty P, May J, Gabriel M, Wölfel R, Günther S, Di Caro A.

J Infect Dis. 2016 Oct 15;214(suppl 3):S250-S257. Epub 2016 Sep 16.

18.

The contribution of the European high containment laboratories during the 2014-2015 Ebola Virus Disease emergency.

Nisii C, Vincenti D, Fusco FM, Schmidt-Chanasit J, Carbonnelle C, Raoul H, Eickmann M, Hewson R, Brave A, Nuncio S, Sanchez-Seco MP, Palyi B, Kis Z, Zange S, Nitsche A, Kurth A, Strasser M, Capobianchi MR, Ozin A, Guglielmetti P, Menel-Lemos C, Jacob D, Grunow R, Ippolito G, Di Caro A.

Clin Microbiol Infect. 2017 Feb;23(2):58-60. doi: 10.1016/j.cmi.2016.07.003. Epub 2016 Jul 9. No abstract available.

19.

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.

Reynard O, Jacquot F, Evanno G, Mai HL, Salama A, Martinet B, Duvaux O, Bach JM, Conchon S, Judor JP, Perota A, Lagutina I, Duchi R, Lazzari G, Le Berre L, Perreault H, Lheriteau E, Raoul H, Volchkov V, Galli C, Soulillou JP.

PLoS One. 2016 Jun 9;11(6):e0156775. doi: 10.1371/journal.pone.0156775. eCollection 2016.

20.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

21.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.

22.

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N; Ebola-Tx Consortium.

N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812.

23.

Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa.

Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fernandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman EN, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CE, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S.

Nature. 2015 Aug 6;524(7563):97-101. doi: 10.1038/nature14594. Epub 2015 Jun 17.

PMID:
26083749
24.

Heparan sulfate-dependent enhancement of henipavirus infection.

Mathieu C, Dhondt KP, Châlons M, Mély S, Raoul H, Negre D, Cosset FL, Gerlier D, Vivès RR, Horvat B.

MBio. 2015 Mar 10;6(2):e02427. doi: 10.1128/mBio.02427-14.

25.

Emergence of Zaire Ebola virus disease in Guinea.

Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S.

N Engl J Med. 2014 Oct 9;371(15):1418-25. doi: 10.1056/NEJMoa1404505. Epub 2014 Apr 16.

26.

Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, Saluzzo JF.

Immunotherapy. 2014;6(6):699-708. doi: 10.2217/imt.14.40. Epub 2014 Mar 27.

27.

Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.

Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C.

PLoS One. 2013;8(3):e58414. doi: 10.1371/journal.pone.0058414. Epub 2013 Mar 14.

28.

Biosafety Level-4 laboratories in Europe: opportunities for public health, diagnostics, and research.

Nisii C, Castilletti C, Raoul H, Hewson R, Brown D, Gopal R, Eickmann M, Gunther S, Mirazimi A, Koivula T, Feldmann H, Di Caro A, Capobianchi MR, Ippolito G.

PLoS Pathog. 2013 Jan;9(1):e1003105. doi: 10.1371/journal.ppat.1003105. Epub 2013 Jan 17. No abstract available.

29.

Type I interferon signaling protects mice from lethal henipavirus infection.

Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, Horvat B.

J Infect Dis. 2013 Jan 1;207(1):142-51. doi: 10.1093/infdis/jis653. Epub 2012 Oct 22.

PMID:
23089589
30.

Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays.

Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z.

Virol Sin. 2012 Oct;27(5):273-7. doi: 10.1007/s12250-012-3252-y. Epub 2012 Sep 21.

PMID:
23001480
31.

H1N1 influenza A virus neuraminidase modulates infectivity in mice.

Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M.

Antiviral Res. 2012 Mar;93(3):374-80. doi: 10.1016/j.antiviral.2012.01.008. Epub 2012 Feb 1.

PMID:
22321413
32.

Role of VP30 phosphorylation in the Ebola virus replication cycle.

Martinez MJ, Volchkova VA, Raoul H, Alazard-Dany N, Reynard O, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S934-40. doi: 10.1093/infdis/jir320.

PMID:
21987772
33.

Conserved proline-rich region of Ebola virus matrix protein VP40 is essential for plasma membrane targeting and virus-like particle release.

Reynard O, Nemirov K, Page A, Mateo M, Raoul H, Weissenhorn W, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S884-91. doi: 10.1093/infdis/jir359.

PMID:
21987765
34.

Unconventional secretion of Ebola virus matrix protein VP40.

Reynard O, Reid SP, Page A, Mateo M, Alazard-Dany N, Raoul H, Basler CF, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S833-9. doi: 10.1093/infdis/jir305.

35.

Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1060-5. doi: 10.1093/infdis/jir347.

36.

Nipah virus uses leukocytes for efficient dissemination within a host.

Mathieu C, Pohl C, Szecsi J, Trajkovic-Bodennec S, Devergnas S, Raoul H, Cosset FL, Gerlier D, Wild TF, Horvat B.

J Virol. 2011 Aug;85(15):7863-71. doi: 10.1128/JVI.00549-11. Epub 2011 May 18.

37.

European perspective of 2-person rule for biosafety level 4 laboratories.

Ippolito G, Nisii C, Di Caro A, Brown D, Gopal R, Hewson R, Lloyd G, Gunther S, Eickmann M, Mirazimi A, Koivula T, Georges Courbot MC, Raoul H, Capobianchi MR.

Emerg Infect Dis. 2009 Nov;15(11):1858. doi: 10.3201/eid1511.091134. No abstract available.

38.

Uranium induces TNF alpha secretion and MAPK activation in a rat alveolar macrophage cell line.

Gazin V, Kerdine S, Grillon G, Pallardy M, Raoul H.

Toxicol Appl Pharmacol. 2004 Jan 1;194(1):49-59.

PMID:
14728979
39.
40.
41.

Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines.

Aillet F, Masutani H, Elbim C, Raoul H, Chêne L, Nugeyre MT, Paya C, Barré-Sinoussi F, Gougerot-Pocidalo MA, Israël N.

J Virol. 1998 Dec;72(12):9698-705.

42.

Nitric oxide synthesis during acute SIV mac251 infection of macaques.

Blond D, Chéret A, Raoul H, Le Grand R, Caufour P, Théodoro F, Dormont D.

Res Virol. 1998 Mar-Apr;149(2):75-86.

PMID:
9602502
43.

HIV type 1 infection of human macrophages induces an upregulation of manganese superoxide dismutase gene that may protect cells from death.

Raoul H, Le Naour R, Blond D, Dormont D.

AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):427-34.

PMID:
9546802
45.

Functional consequences of macrophage infection by human immunodeficiency virus: bispecific antibody targeting of HIV-1-infected cells to Fc gamma RI expressing effector cells.

Mabondzo A, Le Naour R, Le Grand R, Vaslin B, Benveniste O, Cheret A, Raoul H, Romet-Lemonne JL, Dormont D.

J Hematother. 1995 Dec;4(6):579-85.

PMID:
8846019
46.

Relationships between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants.

Mabondzo A, Rouvier P, Raoul H, Le Naour R, Courpotin C, Hervé F, Parnet-Mathieu F, Lasfargues G, Dormont D.

Clin Exp Immunol. 1995 Dec;102(3):476-80.

47.

Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody.

Mabondzo A, Boussin F, Raoul H, Le Naour R, Gras G, Vaslin B, Bartholeyns J, Romet-Lemonne JL, Dormont D.

J Gen Virol. 1994 Jun;75 ( Pt 6):1451-6.

PMID:
8207409
48.
49.
50.

Supplemental Content

Support Center